Actively Recruiting
Study Comparing Reduced-Dose Carboplatin-Doublet Chemotherapy Plus Cemiplimab Versus Cemiplimab Alone in Older and Frail Patients With Metastatic NSCLC and Low PD-L1 Expression
Led by Swiss Cancer Institute · Updated on 2026-10-28
156
Participants Needed
18
Research Sites
104 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating treatment options for patients aged 70 and older with metastatic non-small cell lung cancer NSCLC who have lower than 50% PD-L1 expression and may be frail or in poor health. The study aims to compare the safety and effectiveness of reduced-dose chemotherapy combined with cemiplimab versus cemiplimab alone. This research addresses a gap in evidence for older and frail patients who often cannot tolerate standard chemotherapy doses well. Participants are randomly assigned to one of two groups one receives reduced-dose platinum-doublet chemotherapy combined with cemiplimab, while the other receives cemiplimab monotherapy. The chemotherapy regimens differ according to cancer histology and are given intravenously every three weeks for four cycles, followed by maintenance cemiplimab treatment for up to two years. Patients whose cancer progresses may switch from monotherapy to the combination treatment if suitable. Throughout the study, participants undergo regular imaging scans to assess tumor response every 6 to 12 weeks, along with quality-of-life questionnaires and geriatric assessments of physical function at set intervals. Researchers will monitor progression-free survival, overall survival, response rates, side effects, and overall treatment utility. The trial includes ongoing safety monitoring and aims to provide evidence to improve treatment strategies for older, vulnerable NSCLC patients.
CONDITIONS
Brief Title
Reduced-dose Carboplatin-doublet-chemotherapy + Cemiplimab vs Cemiplimab Monotherapy in Treatment Naive Older and Frail Patients With Metastatic NSCLC With PD-L1 <50%
Research Team
G
Gisela Müller
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here